Annotation Detail
Information
- Associated Genes
- FLT3
- Associated Variants
-
FLT3 ITD
FLT3 ITD - Associated Disease
- acute myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- Forty-seven patients with relapsed/refractory AML or 60+ years old with untreated AML were enrolled on a phase II study. In FLT3 wild-type patients, six out of 36 (17%) had a response (1 PR, 3 MR, 2 uMR) that lasted a median of 58 days (range, 33–273 days). No patient with FLT3-ITD (n = 10) responded. One patient with unknown FLT3 status also had no response. Of note, this study did not meet its primary endpoint of 6 responses (CR, CRi, PR or MR) in the first 35 patients enrolled.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1137
- Gene URL
- https://civic.genome.wustl.edu/links/genes/24
- Variant URL
- https://civic.genome.wustl.edu/links/variants/55
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Acute Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Selumetinib
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 24178622
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Selumetinib | Resitance or Non-Reponse | true |